| Linaclotide | Allergan | ||
| 145,290 mcg; Capsule, Oral |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
None | ||
|
Less Than 5
|
None | ||
| Indicated in adults for the treatment of chronic idiopathic constipation | |||
|
Yes
| |||
| Linzess | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| ********* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| **** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ***** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ********* | *** \ ** | *** **, **** | ******* | ******** | ** *** *, **** |
| **** | *** \ ** | *** **, **** | ******* | **** | ** ***** **, **** |
| ***** | *** \ ** | *** **, **** | ******* | ******** ************ | ** *** *, **** |
| Linaclotide | Allergan | ||
| 72mcg; Capsule, Oral |
More Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
Less Than 5
|
||
| None | None | ||
| Indicated in adults for the treatment of chronic idiopathic constipation | |||
|
Yes
| |||
| Linzess | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 |
|---|---|---|---|---|---|---|---|---|---|
| ***** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| **** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ****** ************ ** *********** | ******* *** ************ *** *** ********* ** **************** ********* | ******* *** ************ *** *** ********* ** **************** ********* | ******* *** ************ *** *** ********* ** **************** ********* | ******* *** ************ *** *** ********* ** **************** ********* | ******* *** ************ *** *** ********* ** **************** ********* | ******* *** ************ *** *** ********* ** **************** ********* | ********** *** **************** ********* | ********** *** **************** ********* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** | *** \ ** | *** **, **** | ******* | **** | ** *** *, **** |
| **** | ** \ ** | *** *, **** | ******* | ********* ******** | ** *** **, **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|